ReviewChest2021
Pulmonary Exacerbations in Adults With Cystic Fibrosis: A Grown-up Issue in a Changing Cystic Fibrosis Landscape.
Review in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 58 citations in OpenAlex.
- Providing Mobile Patient Access to Their Electronic Secondary Care Patient Record in Adults With Cystic Fibrosis: Results of a Prospective, Parallel, Randomized Open-Pilot Quantitative Study.JMIR formative research · 2025Trial
- A Phase IIa, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Brensocatib in Adults with Cystic Fibrosis.Clinical pharmacokinetics · 2025Trial
- Home-Based Connected Devices Combined With Statistical Process Control for the Early Detection of Respiratory Exacerbations by Patients With Cystic Fibrosis: Pilot Interventional Study With a Pre-Post Design.JMIR formative research · 2024Trial
- SOLAR: a noninterventional study of outcomes over the long term of people with cystic fibrosis (CF) aged ≥6 years treated with elexacaftor/tezacaftor/ivacaftor using data from the French CF Registry.ERJ open research · 2026Article
- Clinical Outcomes and Healthcare Resource Utilization Results Among Hospitalized Adults with Cystic Fibrosis Treated with Ceftolozane/Tazobactam: A SPECTRA Real-World Subgroup Analysis.Antibiotics (Basel, Switzerland) · 2026Article
- Decreased pulmonary exacerbations and lower intravenous antibiotic usage following vanzacaftor/tezacaftor/deutivacaftor treatment in people with cystic fibrosis withThe European respiratory journal · 2026Article
- Risk factors for longitudinal estimated glomerular filtration rate decline in adults with cystic fibrosis.Annals of the American Thoracic Society · 2026Article
- A Bayesian Location-Scale Joint Model for Time-To-Event and Multivariate Longitudinal Data With Association Based on Within-Individual Variability.Statistics in medicine · 2026Article
- Host transcriptomic analysis reveals a defective intracellular environment that limits SARS-CoV-2 replication in CFTR-deficient airway epithelium.Frontiers in cellular and infection microbiology · 2026Article
- Pseudomonas aeruginosa infection exacerbates elastase induced lung damage: characterisation of a novel murine two-hit model of pulmonary infection.Respiratory research · 2025Article
- Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025Article
- A chronicInfection and immunity · 2025Article
- Species turnover within cystic fibrosis lung microbiota is indicative of acute pulmonary exacerbation onset.Microbiome · 2025Article
- Pseudomonas aeruginosa faces a fitness trade-off between mucosal colonization and antibiotic tolerance during airway infection.Nature microbiology · 2024Article
- Definition of sinonasal and otological exacerbation in patients with primary ciliary dyskinesia: an expert consensus.ERJ open research · 2024Article
- Therapeutic Interventions forJournal of clinical medicine · 2024Review
- Update on the Role of β2AR and TRPV1 in Respiratory Diseases.International journal of molecular sciences · 2024Review
- Demographic factors associated with within-individual variability of lung function for adults with cystic fibrosis: A UK registry study.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024Article
- Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review.BMJ open respiratory research · 2024Article
- Ceftolozane/Tazobactam for the Treatment of Adults With Cystic Fibrosis: Results From a French Prospective Cohort Study.Open forum infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary exacerbations (PExs) are significant life events in people with cystic fibrosis (CF), associated with declining lung function, reduced quality of life, hospitalizations, and decreased survival. The adult CF population is increasing worldwide, with many patients surviving prolonged periods with severe multimorbid disease. In many countries, the number of adults with CF exceeds the number of children, and PExs are particularly burdensome for adults as they tend to require longer courses and more IV treatment than children. The approach to managing PExs is multifactorial and needs to evolve to reflect this changing adult population. This review discusses PEx definitions, precipitants, treatments, and the wider implications to health-care resources. It reviews current management strategies, their relevance in particular to adults with CF, and highlights some of the gaps in our knowledge. A number of studies are underway to try to answer some of the unmet needs, such as the optimal length of treatment and the use of nonantimicrobial agents alongside antibiotics. An overview of these issues is provided, concluding that with the changing landscape of adult CF care, the definitions and management of PExs may need to evolve to enable continued improvements in outcomes across the age spectrum of CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.